Novo Nordisk A/S (NVO) released headline results Monday from its REIMAGINE 2 Phase 3 trial, and the data looks promising for the company's next-generation weight management therapy.

The Danish pharmaceutical giant already submitted CagriSema for weight management to the FDA back in December 2025, based on results from its REDEFINE 1 and REDEFINE 2 pivotal trials. Now the REIMAGINE program is adding more evidence to the mix, this time focusing on people with type 2 diabetes.

How The Trial Worked

REIMAGINE 2 was a 68-week study that tested once-weekly subcutaneous CagriSema—which combines cagrilintide and semaglutide in fixed doses—against various comparators. The trial enrolled 2,728 people with type 2 diabetes that wasn't adequately controlled on metformin, with or without an SGLT2 inhibitor. About 40% were already using an SGLT2 inhibitor when they entered the study.

Researchers tested two different CagriSema doses (2.4 mg/2.4 mg and 1.0 mg/1.0 mg) against two semaglutide doses (2.4 mg and 1.0 mg), cagrilintide alone (2.4 mg), and placebo. The goal was to see how the combination therapy stacked up on both blood sugar control and weight loss.

The Results Tell A Clear Story

CagriSema delivered better HbA1c reduction and weight loss across all tested doses compared to semaglutide alone. Let's break down the numbers for the highest dose comparison.

Starting from a mean HbA1c baseline of 8.2%, patients treated with CagriSema 2.4 mg/2.4 mg saw their levels drop by 1.91 percentage points after 68 weeks. That compared favorably to the 1.76-point reduction with semaglutide 2.4 mg alone.

The weight loss difference was even more substantial. From a mean baseline of 101 kg (about 223 pounds), people on CagriSema 2.4 mg/2.4 mg lost 14.2% of their body weight after 68 weeks. Those on semaglutide 2.4 mg lost 10.2%—still meaningful, but noticeably less.

Here's something interesting: the trial showed no weight loss plateau at week 68 for CagriSema, suggesting patients might continue losing weight beyond that timeframe. Among those taking the highest CagriSema dose, 43% achieved at least 15% weight loss, and nearly a quarter hit the 20% threshold or higher.

When researchers applied what's called the treatment regimen estimand—a statistical approach that accounts for treatment discontinuation and other factors—the results remained strong. CagriSema 2.4 mg/2.4 mg still achieved 1.80-point HbA1c reduction versus 1.68 points for semaglutide 2.4 mg, and 12.9% weight loss compared to 9.2%.

Safety Profile

The safety data looked consistent with what you'd expect from incretin and amylin-based therapies. CagriSema appeared safe and well-tolerated overall. The most common side effects were gastrointestinal issues, and the vast majority were mild to moderate in severity. These effects tended to diminish over time, which tracks with how similar medications behave.

Stock Movement: Novo Nordisk shares were down 0.61% at $59.07 at the time of publication on Monday.